These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 22686691)

  • 21. Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis.
    Gupta AK; Mays RR; Dotzert MS; Versteeg SG; Shear NH; Piguet V
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2112-2125. PubMed ID: 29797431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapy of androgenetic alopecia with finasteride. What must be considered in consultation and drug prescribing].
    Wolff H; Kunte C
    MMW Fortschr Med; 1999 Sep; 141(37):38-40. PubMed ID: 10897972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transdermal finasteride delivery via powder-carrying microneedles with a diffusion enhancer to treat androgenetic alopecia.
    Kim S; Eum J; Yang H; Jung H
    J Control Release; 2019 Dec; 316():1-11. PubMed ID: 31689460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo.
    Olsen EA; Whiting DA; Savin R; Rodgers A; Johnson-Levonas AO; Round E; Rotonda J; Kaufman KD;
    J Am Acad Dermatol; 2012 Sep; 67(3):379-86. PubMed ID: 22325459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delaying treatment in male-pattern hair loss affects the therapeutic response.
    Rushton DH; Gilkes JJ
    Clin Exp Dermatol; 2011 Mar; 36(2):204-5. PubMed ID: 20659117
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.
    Gupta AK; Talukder M; Williams G
    J Dermatolog Treat; 2022 Nov; 33(7):2946-2962. PubMed ID: 35920739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia.
    Tsunemi Y; Irisawa R; Yoshiie H; Brotherton B; Ito H; Tsuboi R; Kawashima M; Manyak M;
    J Dermatol; 2016 Sep; 43(9):1051-8. PubMed ID: 26893187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients.
    Hu R; Xu F; Sheng Y; Qi S; Han Y; Miao Y; Rui W; Yang Q
    Dermatol Ther; 2015; 28(5):303-8. PubMed ID: 26031764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Finasteride Topical Delivery Systems for Androgenetic Alopecia.
    Khan MZU; Khan SA; Ubaid M; Shah A; Kousar R; Murtaza G
    Curr Drug Deliv; 2018; 15(8):1100-1111. PubMed ID: 29366416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
    Hamilton RJ; Freedland SJ
    BMC Med; 2011 Sep; 9():105. PubMed ID: 21920036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgens and hair loss.
    Alsantali A; Shapiro J
    Curr Opin Endocrinol Diabetes Obes; 2009 Jun; 16(3):246-53. PubMed ID: 19396986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What's New in Therapy for Male Androgenetic Alopecia?
    Saceda-Corralo D; Domínguez-Santas M; Vañó-Galván S; Grimalt R
    Am J Clin Dermatol; 2023 Jan; 24(1):15-24. PubMed ID: 36169916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgenetic alopecia; drug safety and therapeutic strategies.
    Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
    Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety.
    Dhurat R; Sharma A; Rudnicka L; Kroumpouzos G; Kassir M; Galadari H; Wollina U; Lotti T; Golubovic M; Binic I; Grabbe S; Goldust M
    Dermatol Ther; 2020 May; 33(3):e13379. PubMed ID: 32279398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical efficacy of oral administration of finasteride at a dose of 2.5 mg/day in women with female pattern hair loss.
    Won YY; Lew BL; Sim WY
    Dermatol Ther; 2018 Mar; 31(2):e12588. PubMed ID: 29464847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in the treatment of male androgenetic alopecia: a brief review of finasteride studies.
    Whiting DA
    Eur J Dermatol; 2001; 11(4):332-4. PubMed ID: 11399540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia.
    Caserini M; Radicioni M; Leuratti C; Terragni E; Iorizzo M; Palmieri R
    Int J Clin Pharmacol Ther; 2016 Jan; 54(1):19-27. PubMed ID: 26636418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multi-therapies in androgenetic alopecia: review and clinical experiences.
    Rossi A; Anzalone A; Fortuna MC; Caro G; Garelli V; Pranteda G; Carlesimo M
    Dermatol Ther; 2016 Nov; 29(6):424-432. PubMed ID: 27424565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral Finasteride Presents With Sexual-Unrelated Withdrawal in Long-Term Treated Androgenic Alopecia in Men.
    Perez-Mora N; Velasco C; Bermüdez F
    Skinmed; 2015; 13(3):179-83. PubMed ID: 26380503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia.
    Sato A; Takeda A
    J Dermatol; 2012 Jan; 39(1):27-32. PubMed ID: 21980923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.